A simple method for the quantification of diclofenac potassium in oral suspension by high-performance liquid chromatography with UV-detection by Rubim, Alexandre Machado et al.
*Correspondence: A. M. Rubim. Laboratório de Controle de Qualidade de Me-
dicamentos, Departamento de Farmácia, Universidade Federal de Santa Maria, 
Caixa Postal 5083, 97105-900 - Santa Maria-RS. E-mail: rubim9@hotmail.com
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 49, n. 3, jul./sep., 2013
A simple method for the quantification of diclofenac potassium in 
oral suspension by high-performance liquid chromatography with 
UV-detection
Alexandre Machado Rubim1,*, Jaqueline Bandeira Rubenick2, Luciane Varine Laporta2,  
Clarice Madalena Bueno Rolim1
1Department of Pharmacy, Federal University of Santa Maria, 2Laboratory of Control of Drug Quality,  
Franciscan University Center
A rapid, simple and low cost method was developed to determine diclofenac potassium (DP) in oral 
suspension, using a reverse-phase column (C8, 150 mm x 4.6 mm, 5 µm), mobile phase containing 
methanol/buffer phosphate (70:30 v/v, pH 2.5), at a flow rate of 1.0 mL/min, isocratic method, and 
ultraviolet detection at 275 nm. A linear response (r = 1.0000) was observed in the range of 10.0-50.0 µg/
mL. Validation parameters such as linearity, specificity, precision, accuracy and robustness were evaluated. 
The method presented precision (repeatability: relative standard deviation = 1.21% and intermediate 
precision: between-analyst = 0.85%). The specificity of the assay was evaluated by exposure of diclofenac 
potassium under conditions of stress such as hydrolysis, photolysis, oxidation and high temperature. The 
method presented accuracy values between 98.28% and 101.95%. The results demonstrate the validity 
of the proposed method that allows determination of diclofenac potassium in oral suspension and may 
be used as an alternative method for routine analysis of this product in quality control. 
Uniterms: High performance liquid chromatography. Diclofenac potassium. Oral suspension.
Desenvolveu-se método simples, de baixo custo para determinar o diclofenaco potássico (DP) em 
suspensão oral, usando coluna de fase reversa (C8, 150 mm x 4,6 mm, 5 µm), fase móvel contendo 
metanol/tampão fosfato (70:30 v/v, pH 2,5), com fluxo de 1,0 mL/min, método isocrático e detecção no 
ultravioleta a 275 nm. Observou-se resposta linear (r = 1,0000) na faixa de 10,0-50,0 µg/mL. Avaliaram-
se parâmetros de validação, como linearidade, especificidade, precisão, exatidão e robustez. O método 
apresentou precisão (repetibilidade: desvio padrão relativo = 1,21% e precisão intermediária: entre analista 
= 0,85%). A especificidade do ensaio foi avaliada pela exposição do diclofenaco potássico a condições 
de estresse, tais como hidrólise, fotólise, oxidação e alta temperatura. O método apresentou valores de 
exatidão entre 98,28% e 101,95%. Os resultados mostram a validade do método proposto, que permite 
a determinação de diclofenaco potássico em suspensão oral e pode ser utilizado como alternativa para 
análise de rotina desse produto no controle de qualidade. 
Unitermos: Cromatografia de alta eficiência. Diclofenaco potássico. Suspensão oral. 
INTRODUCTION
Diclofenac potassium (DP), 2-[(2,6-dichlorophenyl)-
amino]-benzeneacetic acid, is an acid phenyl acetic 
derivative with anti-inflammatory, analgesic and anti-
thermal properties. It is usually found as potassium and 
sodium. This drug is indicated for rheumatoid arthritis, 
degenerative joint disease, chronic pain associated with 
cancer and kidney stones and endodontic procedures 
(Farmacopéia Brasileira, 2010; Sanches, Viletti, 2009; 
Silva, 2010). Analytical methods have been described 
in literature for the determination of DP in tablets and 
human serum by HPLC and spectrophotometry (Elkady, 
2010; Naidoo et al., 2009; Souza, Tubino, 2005; Sparidans 
et al., 2008). Official physicochemical techniques for 
the quality control of DP in raw material and tablets are 
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described in British Pharmacopeia (BP, 2012). The United 
States Pharmacopeia and Brazilian Pharmacopeia employ 
techniques such as titration in non-aqueous medium, 
spectrophotometry and LC (Farmacopéia Brasileira, 2010; 
USP, 2012).
The development of analytical, safe and reliable 
methods is a very important tool for the quality control of 
pharmaceutical products and raw material. For this reason 
many authors have published articles on the subject (Arend 
et al., 2009; Nogueira et al., 2007; Rosa et al., 2008).
Due to  the  lack of  a  methodology for  the 
determination of DP in oral suspension this study aimed to 
develop and validate a methodology for the determination 
of diclofenac potassium in oral suspension for routine 
analysis in laboratories. This method was validated 
according to the official guidelines (Brasil, 2003; ICH, 
2005; Inmetro, 2007).
MATERIAL AND METHODS
Chemical and Reagents
DP reference substance was obtained from 
Farmacopeia Brasileira, batch 1053. DP oral suspension 
(Cataflam®) was purchased from the Brazilian market. All 
chemicals used were of analytical grade and all solvents 
were LC grade. Methanol and phosphate sodium were 
purchased from Sigma Aldrich. The purified water used 
was obtained utilizing the reverse osmosis system (Milli-Q 
Millipore Corporation®).
Equipment and Chromatographic conditions
The development and validation of the assay was 
performed on a Shimadzu LC system (Kyoto Japan), 
with an LC-20AT pump, SIL-20A ht automatic injector, 
CTO-20AC column oven, SPD-M20A photodiode array 
detector (PDA) and CBM-20A controller with LC solution 
software. Chromatographic separations were achieved 
using a Phenomenex® Luna C8 (150 x 4.6 mm, 5 µm) 
column. The mobile phase and diluent contained a mixture 
of methanol: buffer phosphate pH 2.5 (70:30 v/v) and 
methanol: water (70:30 v/v) respectively, flow of 1.0 mL/
min, PDA detection at 275 nm. The injection volume was 
20 µL.
Preparation of Standard Solution
10.0 mg of diclofenac potassium reference substance 
was accurately weighed and dissolved in a 10 mL 
volumetric flask with diluents. This solution was diluted 
appropriately in the range from 10.0 to 50.0 µg/mL, with 
an average concentration of 30.0 µg/mL.
Preparation of Sample Solution
An aliquot equivalent of 2.0 mg of DP, about 1.0 mL 
of oral suspension was transferred to a 10.0 mL volumetric 
flask and dissolved with diluents. Then a 1.5 mL aliquot 
was pipetted into a 10 mL volumetric flask and diluted 
with the same solvent.
Validation Study
Specificity
Placebo, sample oral suspension and DP reference 
substance solution were analyzed for the determination 
of method specificity. The placebo formulation contains: 
citric acid, sorbic acid, deionized water, strawberry 
flavor, cellulose microcrystalline, sodium cyclamate, 
hydroxyethylcellulose, propylparaben, methylparaben, 
propylene glycol, glyceryl polyoxyethyleno glycol 
stearate, saccharin sodium.
Moreover, the specificity was evaluated for stress 
testing (ICH, 2005). The stress conditions follow: 
Hydrolytic Conditions
Individually, 25.0 mg of DP reference substance 
were dissolved in a 25 mL volumetric flask with diluent to 
generate a concentration of 1 mg/mL. Then 5 mL aliquots 
were transferred to a 25 mL volumetric flask and dissolved 
in HCl 0.1 M and NaOH 0.1 M. After 5 and 24 hours, 
aliquots of 1.5 mL were transferred to a 10 mL volumetric 
flask and neutralized with NaOH 0.1 M and HCl 0.1 M, 
respectively.
Oxidative Condition
The equivalent of 25.0 mg of DP reference substance 
was dissolved in a 25 mL volumetric flask with diluent 
to generate a concentration of 1 mg/mL. After that, 5 mL 
aliquots were transferred to a 25 mL volumetric flask and 
dissolved in hydrogen peroxide 3%. After, 5 and 24 hours, 
1.5 mL aliquots were transferred to a 10 mL volumetric 
flask dissolved in diluents.
Photolytic degradation
The equivalent of 25.0 mg of DP reference substance 
was dissolved in a 25 mL volumetric flask with diluent 
to generate a concentration of 1 mg/mL. After that, 5 mL 
aliquots were transferred to a 25 mL volumetric flask 
and dissolved in diluents. This solution was exposed to 
UV light (ʎ = 254 nm) for 5 and 24 hours. Then a 1.5 mL 
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aliquot was transferred to a 10 mL volumetric flask and 
dissolved in diluents. All the solutions were analyzed in 
triplicate.
Linearity and range
The linearity was determined by constructing three 
independent analytical curves, with five concentrations 
of DP (10.0; 20.0; 30.0; 40.0 and 50.0 µg/mL), which 
were analyzed in triplicate on three consecutive days. The 
results were subjected to regression analysis by the least 
squares method to calculate the calibration curves.
Detection Limit and Quantification Limit
The detection limit (DL) and quantification limit 
(QL) were based on the standard deviation of the response 
and the slope of the mean of three calibration curves.
Precision and Accuracy
The precision assay was investigated with respect 
to repeatability (intra-day) and intermediate precision 
(inter-day). The repeatability was evaluated by assaying 
three determinations at concentrations of 10.0; 30.0 and 
50.0 µg/mL, during same day and under the same 
experimental conditions. The intermediate precision was 
assessed by carrying out the same analysis on 3 different 
days. The precision was expressed as % of relative 
standard deviation (RSD).
Accuracy was evaluated from the amount of DP 
reference substance recovered. The study was performed 
by adding a known amount of DP standard solution (10.0; 
20.0; 30.0 and 40.0 µg/mL) to sample solution. The actual 
and the measured concentration were then compared. The 
experiments were repeated three times. 
Robustness
The robustness evaluation of the chromatographic 
method for DP was performed using the method proposed 
by Youden and Steiner (1975). Five analytical parameters 
were selected and small variations were induced in 
the nominal values of the method. The five analytical 
parameters employed, as well as the variations introduced 
are shown in Table I. Then, eight runs were performed 
aiming to determine the influence of each parameter in the 
final results, according to a matrix of factors in Table II.
The parameters A, a, B, b, C, c, D, d, E, e, were 
calculated according to equations (equations 1-10) as 
follows: 
According to Nogueira et al. (2011), this method 
will be robust if conditions 1 and 2 are met:
Condition 1: (for factor A and other factors) content 
of DP – 5% ≤ A ≤ content of DP + 5%.
Condition 2: (for factor A and other factors) 
A – a ≤ 3% involving the DP content.
An appropriate amount was transferred into an 
individual 10 mL volumetric flask, diluted to volume 
with diluents, and filtered through a 0.45 μm membrane 
filter (Millipore, Bedford, USA), obtaining the final 
concentration of 30.0 µg/mL of the active pharmaceutical 
ingredient. The concentrations of DP presented in samples 
were determined from the standard curve.
System Suitability
System suitability was evaluated by five replicate 
analyses of a DP reference substance and sample at a 
concentration of 30.0 µg/mL. The calculated parameters 
were: number of theoretical plates, tailing factor and 
asymmetry (FDA, 1994).
RESULTS AND DISCUSSION
System Suitability 
To obtain the best chromatographic method, the 
mobile phase of methanol and buffer phosphate (70:30 
v/v, pH 2.5) was utilized to provide adequate peak and 
satisfactory results according to criteria evaluated. A 
TABLE I - Analytical parameters and variations to evaluate the 
robustness of the chromatographic method for DP quantification
Parameter Variation
Mobile phase flow rate 
(mL min-1)
A - 1.2 a - 0.8
Column supplier B - Gemini b - Sunfire
Column temperature (ºC) C - 30 c - 20
Methanol concentration in 
mobile phase (%)
D - 73 d - 67
Time of ultrasonic bath for 
preparation sample (min)
E - 25 e - 15
TABLE II - Matrix of factors for the determination of method 
robustness
Value of 
factor
Combination assayed
1 2 3 4 5 6 7 8
A or a A A A A a a a a
B or b B B b b B B b B
C or c C c C c C c C c
D or d D D d d d d D D
E or e E e E e e E e E
Results s t u v w x y z
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150 mm length octylsilane column was able to obtain a 
resolution and peak asymmetry and a time analytical short 
when compared, for example to the method used for the 
determination of diclofenac in the raw material and tablets.
Specificity
The chromatograms obtained with the specificity 
test (Figure 1), showed that none of the excipients of the 
formulation eluted in the same retention time were related 
to the DP peak. Therefore none of them interfered in its 
determination.
Furthermore,  the interference of potential 
degradation products was investigated through a forced 
degradation test. These studies were performed to identify 
the key factors which will impact the drug stability, as well 
as verify that the method is useful for stability studies. 
Usually the range of degradation is 10% to 30% (Chan 
et al., 2004).
Basic Conditions
After alkali hydrolysis, the concentration remained 
constant and no degradation of the DP reference substance 
was found. The stress test did not show the formation of 
secondary peaks in the chromatogram.
Acidic Conditions
After zero, 5 and 24- hour hydrolysis times, a 
reduction in area of around 8.3%, 39.0% and 45.6% 
occurred respectively, according to Figure 2.
FIGURE 1 - Chromatograms corresponding to: (a) solution of DP reference substance, (b) oral suspension sample and (c) sample 
placebo.
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Oxidative Conditions
After chemical oxidation with H2O2 3%, during a 
24-hour period, a reduction of area around 14.6% and 
43.0% occurred at 5 and 24 hours respectively, according 
to Figure 3.
Photolytic degradation
Under photolytic condition the average area for DP 
showed a reduction of about 86.5% at the end of 24 hours, 
according to Figure 4.
In conclusion, stress degradation tests under the 
conditions described showed that DP degraded partially 
under acidic, oxidative and photolytic conditions. 
Although degradation of the drug occurs under acid 
and oxidative conditions, there was no appearance 
of secondary peaks related to degradation products. 
Under acidic and oxidative conditions there was no 
appearance of secondary peaks related to degradation 
products, which may be explained by the fact that they 
do not have chromophoric groups in their molecule, 
present low concentrations or are detected after the end 
of the run. After 24 hours under photolytic conditions, 
the drug degraded, as did the appearance of new peaks 
in the chromatogram related to potential degradation 
products.
The method proposed can be used to indicate 
stability because the peak of the parent drug does not suffer 
interference from other signals in the chromatograms. 
The purity of peaks was attested with photodiode detector 
support.
FIGURE 2 - Chromatograms corresponding to: (a) solution of DP reference substance time zero, (b) solution of DP reference 
substance time 5 hours and (c) solution of DP reference substance time 24 hours after acid hydrolysis conditions.
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Linearity and range
Linearity was observed over the concentration 
range of 10.0-50.0 µg/mL, according to Figure 5, with 
a correlation coefficient of (r = 1.0000) according to 
the criteria established for (r = 0,9999) and the linear 
regression equation y = 44934x + 36300 (where, x is 
concentration and y is the peak absolute area). Assay 
validity was verified by means of the ANOVA. According 
to the statistical data, there is a linear relationship between 
the variables and there is no deviation from linearity 
(p < 0.05). The quantification and detection limits were 
0.05 µg/mL and 0.02 µg/mL respectively showing method 
sensibility.
Precision
The precision of the method was evaluated as 
repeatability and intermediate precision and was expressed 
as RSD%. The mean results were 1.21% and 0.85% of 
RSD respectively. The limit for this assay is an RSD 
maximum of 2.0% (USP, 2012).
Accuracy
Accuracy was calculated as the percentage of 
recovery by the assay of the known added amount DP 
reference substance in solutions, using three concentration 
levels and three replicates of each concentration. The 
average percentage obtained was 98.28%–101.95% 
satisfying the acceptance criteria for the study.
Robustness
The method described by Youden and Steiner 
(1975), makes it possible not only to evaluate method 
FIGURE 3 - Chromatograms corresponding to: (a) solution of DP reference substance time zero, (b) solution of DP reference 
substance time 5 hours and (c) solution of DP reference substance time 24 hours after oxidative conditions.
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FIGURE 4 - Chromatograms corresponding to: (a) solution of DP reference substance time 5 hours and (b) solution of DP reference 
substance time 24 hours after photolytic conditions.
FIGURE 5 - Calibration curve of Diclofenac potassium.
robustness, but also to sort the variation of each parameter 
in the final results (INMETRO, 2007). Results presented 
in Tables III and IV, indicate satisfactory robustness of 
the method.
After variation of some parameters of the method 
proposed, these variations were not able to significantly 
change the DP content in the sample, average levels of 
DP ranging from 98.43% to 102.34%. The results satisfy 
conditions 1 and 2, and were therefore considered a robust 
method for the determination of DP in oral suspension.
CONCLUSION
The proposed liquid chromatography method 
provides specific, accurate, precise and robust results for 
TABLE III - Combinations tested to evaluate the robustness of the analytical method, evaluating the conditions 1
Combination assay
Results s t u v w x y z
Content (%): 99.52 101.50 99.76 100.43 101.34 101.14 98.43 102.34
Average content (%): 100.56
RSD (%): 1.26
Acceptable range for content of DP (%):     96.14% ≤ 101.20 ≤ 106.26%
*average of three determinations; RSD – relative standard deviation
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TABLE IV - Combinations tested to evaluate the robustness 
Content of DP (%) Difference (%) Limits for the difference (%) (3%*101.21%)
A = 100.30 a = 100.81 A – a = - 0.51 3.04 Robust
B = 100.87 b = 100.24 B – b = 0.63 3.04 Robust
C = 99.76 c = 101.35 C – c = - 1.59 3.04 Robust
D = 100.44 d = 100.66 D – d = - 0.22 3.04 Robust
E = 100.69 e = 100.42 E – e = 0.27 3.04 Robust
Average (%)* (A,a,B,b,C,c,D,d,E,e): 100.55
SD: 0.43
RSD (%): 0.43
*average for three determinations; SD: standard deviation; RSD: relative standard deviation
the quantitative determination of DP in oral suspension. 
Hence, the method developed represents an alternative in 
the routine of pharmaceuticals laboratories, and is suitable 
to determine DP in the quality control routine for the 
pharmaceutical form.
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